Digipath
CHM Cannabis
Home > Boards > US Listed > Biotechs >

Invitae Corp. (NVTA)

NVTA RSS Feed
Add NVTA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/11/2018 1:29:15 PM - Followers: 13 - Board type: Free - Posts Today: 0

Genetics is the future of medicine.
TOGETHER WE CAN IMPROVE HEALTHCARE FOR BILLIONS OF PEOPLE.

Our vision.

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.

Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.

What’s our plan? It takes three steps:

Make genetic testing more affordable and accessible than ever before.
Build a secure and trusted genome management infrastructure.
Design a new global community for sharing genetic information to advance science and medicine.
DOWNLOAD BROCHURE
Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.
Making genetic testing affordable and accessible.

Today, Invitae can deliver results for any genetic test in our catalog for $1,500 in an average of three weeks.

As a part of that catalog, the company currently offers the following panels:

Featured cancer panels

BRCA1 and BRCA2, including full gene sequencing and deletion/duplication analysis
Hereditary breast cancer, high-risk panel (7 genes)
Hereditary breast cancer, extended panel (12 genes)
Women’s hereditary cancer panel (18 genes associated with hereditary breast, ovarian and endometrial cancer)
Lynch syndrome (5 genes)
Hereditary colon cancer, high-risk panel(7 genes)
Hereditary colon cancer (14 genes)
Hereditary pancreatic cancer (17 genes)
Hereditary cancer syndromes panel (29 genes)
Featured cardiology panels

Brugada syndrome (10 genes)
Long QT syndrome (13 genes)
Hypertrophic cardiomyopathy (16 genes)
Short QT syndrome (6 genes)
Featured neurology panels

Charcot-Marie Tooth disease (28 genes)
Hereditary spastic paraplegia (17 genes)
Additionally, Invitae is committed to improving family health by leveraging the power of genetic information and innovative technologies. The “Invitae Family History Tool” is the first free family history collection app that enables genetic counselors to digitally build, modify, share, and save their patients’ pedigrees.

Learn more about the Family History Tool.
An unparalleled team.

Invitae has assembled a team of more than 130 of the world’s foremost experts in genetics, bioinformatics, engineering, technology, and commercial development, among other disciplines. The company was founded in 2012 by CEO Randy Scott (co-founder of Genomic Health [Nasdaq: GHDX] and Incyte [Nasdaq: INCY]) through an investment in Locus Development, founded by Sean George, Michele Cargill, Alex Furman and Mat Falkowski.



Since its inception, Invitae has collectively raised $207 million.
Digipath
CHM Cannabis
NVTA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVTA News: New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients 12/10/2018 07:30:00 AM
NVTA News: Statement of Changes in Beneficial Ownership (4) 11/16/2018 06:11:27 PM
NVTA News: Statement of Changes in Beneficial Ownership (4) 11/16/2018 06:09:43 PM
NVTA News: Invitae Highlighting New Research, Honoring Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC)... 11/14/2018 07:30:00 AM
NVTA News: Quarterly Report (10-q) 11/07/2018 05:06:47 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#57   Sure am; shub 12/11/18 01:29:15 PM
#56   You still in this? Thedeadman 11/29/18 08:33:57 PM
#55   It was around 5 or 6$ when i shub 09/19/18 02:02:39 PM
#54   It got pretty darn low there and hasn't shub 05/21/18 03:14:23 PM
#53   Been wanting to buy, just won't pullback any, madprophet 05/21/18 02:42:37 PM
#52   Yeah: I'm no trader..Research, buy and squat on shub 05/10/18 04:50:09 PM
#51   I believe you are right-- great potential. Eye chmcnfunds 05/10/18 04:22:41 PM
#50   Too soon. shub 05/10/18 03:46:26 PM
#49   Out for now @ $5.67 near the EOD. chmcnfunds 04/11/18 04:05:33 PM
#48   Very nice, was hoping for +10%, but keeps chmcnfunds 04/11/18 01:32:05 PM
#47   InVitae +3.7% as Baker Bros. reports 12.6% stake chmcnfunds 04/11/18 10:05:04 AM
#46   Up after hours (but can't trade with E-trade chmcnfunds 04/10/18 04:17:26 PM
#45   Invitae research highlights utility of proactive genetic screening, chmcnfunds 04/10/18 09:28:41 AM
#44   Assessing Invitae's Flub This Week chmcnfunds 04/02/18 11:25:01 AM
#43   The big loser is top holder because all chmcnfunds 03/28/18 08:57:58 AM
#42   Can't believe they would price it less ($4.50) chmcnfunds 03/28/18 08:48:05 AM
#41   This Explains Why Invitae Is Sinking Today chmcnfunds 03/27/18 12:50:42 PM
#40   Added @ $6.00 -- got to be near bottom: chmcnfunds 03/27/18 09:56:38 AM
#39   Back in NVTA @ $6.20. Seem to recall chmcnfunds 03/27/18 09:39:45 AM
#38   FWIW, I rarely make comments when not currently chmcnfunds 03/08/18 08:36:44 AM
#37   NVTA starts trading over the 50dma good sign JefftDecker 03/08/18 08:34:39 AM
#36   another positive close, going strong JefftDecker 03/07/18 06:57:50 PM
#35   NVTA you gotto hold until the chart says otherwise JefftDecker 03/06/18 11:41:22 AM
#34   Out at $6.85 at EOD for a loss. chmcnfunds 03/02/18 03:56:41 PM
#33   NVTA yeah i really thought also JefftDecker 02/27/18 05:47:24 PM
#32   Invitae expands existing credit facility to provide up chmcnfunds 02/27/18 04:16:12 PM
#31   All in all pretty good day considering. Keeping chmcnfunds 02/27/18 04:03:43 PM
#30   NVTA JefftDecker 02/26/18 10:31:09 PM
#29   NVTA JefftDecker 02/26/18 10:28:51 PM
#28   Thankfully it is. Held through the earning which chmcnfunds 02/26/18 08:11:24 AM
#27   NVTA- starting to show some turn around here lately JefftDecker 02/25/18 07:49:54 AM
#26   In @ $7.80 on a major sell-off this chmcnfunds 01/12/18 02:08:02 PM
#25   With our potential for growth; shub 09/12/17 02:58:32 PM
#24   Looking like buildup of very desirable AI gene x1power 09/07/17 11:54:51 AM
#23   Looks like we are acquiring 2 smaller genetics shub 08/01/17 01:43:42 PM
#22   "ASCO Data Shows Prostate Cancer Patients with Genetic shub 06/05/17 03:54:14 PM
#21   Wow! "Invitae Exceeds 26,000 Samples Accessioned". Thats 166% more shub 05/09/17 03:04:51 PM
#20   We keep expanding our offerings at a brisk shub 03/23/17 01:23:08 PM
#19   Up to 10.30 and about to present 17 shub 03/15/17 04:12:42 PM
#18   9.83 just now...Buncha upgrades and very impressive growth shub 02/14/17 02:42:55 PM
#17   Pre market over 10.50. Probably drop some Matrix999 02/14/17 08:58:03 AM
#16   Well, RE the PPS, that seems to be shub 02/13/17 02:45:34 PM
#15   This puppy is roaring! shub 01/09/17 03:35:19 PM
#14   NVTA bearish 7.35 stocktrademan 11/26/16 07:12:14 PM
#13   Brigar: Making a stock decision based on a message shub 09/13/16 03:48:38 PM
#12   The story seems tasty and the services seem shub 09/01/16 02:25:21 PM
#11   NVTA bearish 7.86 stocktrademan 06/17/16 12:52:20 PM
#10   Chart been rallying, any thoughts on continuation into Christie Mensch 11/29/15 07:35:18 PM
#9   10-Q Cash $68M O/S 31.8M RealGenius 05/17/15 08:44:40 PM
#8   a "friend" in the industry telling you inside brigar6 04/23/15 08:32:47 AM
PostSubject